318 related articles for article (PubMed ID: 30892132)
1. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.
Liu H; Guo L; Zhang J; Zhou Y; Zhou J; Yao J; Wu H; Yao S; Chen B; Chai Y; Qi J; Gao GF; Tan S; Feng H; Yan J
MAbs; 2019; 11(4):681-690. PubMed ID: 30892132
[TBL] [Abstract][Full Text] [Related]
2. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China.
Zhang L; Hao B; Geng Z; Geng Q
Front Immunol; 2021; 12():730666. PubMed ID: 35095833
[TBL] [Abstract][Full Text] [Related]
3. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
Rajasekaran N; Wang X; Ravindranathan S; Chin DJ; Tseng SY; Klakamp SL; Widmann K; Kapoor VN; Vexler V; Keegan P; Yao S; LaVallee T; Khare SD
Cancer Immunol Immunother; 2024 Feb; 73(3):60. PubMed ID: 38400933
[TBL] [Abstract][Full Text] [Related]
4. PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
Lu D; Xu Z; Zhang D; Jiang M; Liu K; He J; Ma D; Ma X; Tan S; Gao GF; Chai Y
Front Immunol; 2022; 13():826045. PubMed ID: 35309324
[TBL] [Abstract][Full Text] [Related]
5. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M
Commun Biol; 2019; 2():392. PubMed ID: 31667366
[TBL] [Abstract][Full Text] [Related]
6. GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy.
Kim HM; Kim KJ; Lee K; Yoon MJ; Choih J; Hong TJ; Cho EJ; Jung HJ; Kim J; Park JS; Na HY; Heo YS; Park CG; Park H; Han S; Bae D
BMC Immunol; 2024 May; 25(1):29. PubMed ID: 38730320
[TBL] [Abstract][Full Text] [Related]
7. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J
Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004
[TBL] [Abstract][Full Text] [Related]
8. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
[TBL] [Abstract][Full Text] [Related]
9. Toripalimab for the treatment of melanoma.
Tang B; Chi Z; Guo J
Expert Opin Biol Ther; 2020 Aug; 20(8):863-869. PubMed ID: 32406293
[TBL] [Abstract][Full Text] [Related]
10. Toripalimab: First Global Approval.
Keam SJ
Drugs; 2019 Apr; 79(5):573-578. PubMed ID: 30805896
[TBL] [Abstract][Full Text] [Related]
11. Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor.
Liu J; Wang G; Liu L; Wu R; Wu Y; Fang C; Zhou X; Jiao J; Gu Y; Zhou H; Xie Z; Sun Z; Chen D; Dai K; Wang D; Tang W; Yang TTC
Sci Rep; 2019 Nov; 9(1):17830. PubMed ID: 31780710
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.
Li F; Li J; Yin K; Zhang J; Li ZH; Lu L; Bao YW; Qin Z; Zheng Y; Yang BT; Li J; Wang X
Acta Pharmacol Sin; 2021 Jan; 42(1):142-148. PubMed ID: 32467569
[TBL] [Abstract][Full Text] [Related]
14. N-glycosylation of PD-1 promotes binding of camrelizumab.
Liu K; Tan S; Jin W; Guan J; Wang Q; Sun H; Qi J; Yan J; Chai Y; Wang Z; Deng C; Gao GF
EMBO Rep; 2020 Dec; 21(12):e51444. PubMed ID: 33063473
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Lee SH; Lee HT; Lim H; Kim Y; Park UB; Heo YS
Biochem Biophys Res Commun; 2020 Jun; 527(1):226-231. PubMed ID: 32446372
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
Wei XL; Ren C; Wang FH; Zhang Y; Zhao HY; Zou BY; Wang ZQ; Qiu MZ; Zhang DS; Luo HY; Wang F; Yao S; Xu RH
Cancer Commun (Lond); 2020 Aug; 40(8):345-354. PubMed ID: 32589350
[TBL] [Abstract][Full Text] [Related]
19. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
[TBL] [Abstract][Full Text] [Related]
20. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
